Addressing the need for patient-friendly medical communications: adaptation of the 2019 recommendations for the management of MPS VI and MPS IVA.
Anesthetics
Enzyme replacement therapy
MPS IVA
MPS VI
Management guidelines
Mucopolysaccharidosis
Patient education
Patient engagement
Rare diseases
Surgery
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 03 2022
02 03 2022
Historique:
received:
10
08
2021
accepted:
06
02
2022
entrez:
3
3
2022
pubmed:
4
3
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Patients are the most important stakeholders in the care of any disease and have an educational need to learn about their condition and the treatment they should receive. Considering this need for patient-focused materials, we present a directed approach for mucopolysaccharidosis (MPS) VI and MPS IVA, a pair of rare, inherited diseases that affects multiple organs and parts of the body. Independent guidelines on the treatment of these diseases were recently published, providing evidence- and expertise-driven recommendations to optimize patient management. However, while healthcare providers may have the training and knowledge to understand these guidelines, patients and their caregivers can find the technical content challenging. Hence, we aimed to develop plain language summaries (PLS) of the MPS VI and MPS IVA guidelines with patients as the primary audience. A review of the guidelines by an expert team identified six domains of information relevant to patients: The multidisciplinary team, regular tests and check-ups, disease-modifying and supportive treatments, general anesthetics, ear-nose-throat/respiratory care, and surgeries. This information was adapted into a series of infographics specific to either MPS VI or MPS IVA, designed to appeal to patients and clearly present information in a concise manner. The use of patient-friendly materials, like the infographics we have developed, has the potential to better inform patients and engage them in their care. We issue a "call to arms" to the medical community for the development of similar PLS materials in rare diseases intended to inform and empower patients.
Sections du résumé
BACKGROUND
Patients are the most important stakeholders in the care of any disease and have an educational need to learn about their condition and the treatment they should receive. Considering this need for patient-focused materials, we present a directed approach for mucopolysaccharidosis (MPS) VI and MPS IVA, a pair of rare, inherited diseases that affects multiple organs and parts of the body. Independent guidelines on the treatment of these diseases were recently published, providing evidence- and expertise-driven recommendations to optimize patient management. However, while healthcare providers may have the training and knowledge to understand these guidelines, patients and their caregivers can find the technical content challenging. Hence, we aimed to develop plain language summaries (PLS) of the MPS VI and MPS IVA guidelines with patients as the primary audience.
RESULTS
A review of the guidelines by an expert team identified six domains of information relevant to patients: The multidisciplinary team, regular tests and check-ups, disease-modifying and supportive treatments, general anesthetics, ear-nose-throat/respiratory care, and surgeries. This information was adapted into a series of infographics specific to either MPS VI or MPS IVA, designed to appeal to patients and clearly present information in a concise manner.
CONCLUSIONS
The use of patient-friendly materials, like the infographics we have developed, has the potential to better inform patients and engage them in their care. We issue a "call to arms" to the medical community for the development of similar PLS materials in rare diseases intended to inform and empower patients.
Identifiants
pubmed: 35236367
doi: 10.1186/s13023-022-02219-7
pii: 10.1186/s13023-022-02219-7
pmc: PMC8889702
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
91Informations de copyright
© 2022. The Author(s).
Références
Childs Nerv Syst. 2015 Feb;31(2):203-12
pubmed: 25358811
J Gen Intern Med. 2014 Aug;29 Suppl 3:S788-800
pubmed: 25047393
BMJ Open. 2019 Dec 29;9(12):e033353
pubmed: 31888936
Curr Rheumatol Rep. 2014 Jan;16(1):389
pubmed: 24264718
J Med Internet Res. 2022 Jan 11;24(1):e22122
pubmed: 35014966
J Inherit Metab Dis. 2014 Jan;37(1):1-12
pubmed: 23653226
Mayo Clin Proc. 2017 Mar;92(3):423-433
pubmed: 28259229
Ther Innov Regul Sci. 2018 Jul;52(4):474-481
pubmed: 29714545
Mol Genet Genomic Med. 2017 Nov;5(6):758-773
pubmed: 29178638
Chin Med J (Engl). 2018 Oct 20;131(20):2514-2517
pubmed: 30334544
PLoS One. 2017 Jan 18;12(1):e0170365
pubmed: 28099516
Curr Pharm Biotechnol. 2011 Jun;12(6):931-45
pubmed: 21506915
Biochem Res Int. 2012;2012:471325
pubmed: 22013531
Orphanet J Rare Dis. 2010 Apr 12;5:5
pubmed: 20385007
Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v4-12
pubmed: 22210669
EMBO Mol Med. 2019 May;11(5):
pubmed: 30979709
Orphanet J Rare Dis. 2019 May 29;14(1):118
pubmed: 31142378
Orphanet J Rare Dis. 2019 Jan 24;14(1):21
pubmed: 30678705
Orphanet J Rare Dis. 2019 Jun 13;14(1):137
pubmed: 31196221
Mol Genet Metab. 2013 May;109(1):54-61
pubmed: 23452954